Effect of Febuxostat on Blood Pressure

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: December 18, 2011
Last updated: July 31, 2015
Last verified: July 2015
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with gout).

Condition Intervention Phase
Drug: Febuxostat
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6 [ Time Frame: Baseline and Week 6 ] [ Designated as safety issue: No ]
    The change in 24-hour mean SBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Secondary Outcome Measures:
  • Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring at Week 6 [ Time Frame: Baseline and Week 6 ] [ Designated as safety issue: No ]
    The change in 24-hour mean DBP measured at final visit or Week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

  • Change From Baseline in Serum Urate Levels at Week 6 [ Time Frame: Baseline and Week 6 ] [ Designated as safety issue: No ]

Enrollment: 121
Study Start Date: February 2012
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Febuxostat 80 mg QD
Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
Drug: Febuxostat
Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
Other Names:
  • TMX-67
  • Uloric
Placebo Comparator: Placebo QD
Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Drug: Placebo
Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.

Detailed Description:
This study is designed to evaluate the effect of febuxostat during 6 weeks of treatment.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The participant has documented hypertension, defined as average clinic systolic blood pressure (SBP) of ≥145 mm Hg and ≤165 mm Hg or average clinic diastolic blood pressure (DBP) of ≥90 mm Hg and ≤105 mm Hg at the Day -21 Screening Visit; the average BP measurement at two of the three Placebo Run-in Visits (Day -14, Day -7 and Day -1) must also meet the above criteria for hypertension.
  2. The participant has a serum uric acid (sUA) level ≥7.0 mg/dL not associated with gout, at the Day -21 Screening Visit.
  3. The participant has a 24-hour mean ambulatory SBP of ≥130 mm Hg and < 165 mm Hg at the Baseline (Day 1) Visit.
  4. At the initial Screening Visit (Day -21), the maximum number of antihypertensive medications the participant is taking is ≤ 2 (fixed-dose combination medications are considered 2 medications, including diuretics), and the participant has been on a stable dose of this medication for at least1 month prior to start of the initial Screening Visit (Day -21).
  5. The participant is male and at least 18 years of age, or a female who is:

    • Surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation), OR
    • Postmenopausal (defined as at least 1 year since last regular menses with an follicle-stimulating hormone (FSH) >40 IU/L, or at least 5 years since last regular menses), OR
    • On hormone replacement therapy and ≥ 55 years of age.
  6. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  7. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

Exclusion Criteria:

  1. The participant has received any investigational compound within 30 days, or within 5 half-lives of the compound (whichever is longer) prior to the Screening Visit.
  2. The participant has received febuxostat or any urate-lowering therapy (ULT) in a previous clinical study or as a therapeutic agent.
  3. The participant has gout, history of gout, or gout flares.
  4. The participant has secondary hyperuricemia (HPU) (e.g., due to myeloproliferative disorder, or organ transplant).
  5. The participant has known secondary hypertension of any etiology (e.g., renovascular disease, primary hyperaldosteronism, Cushing syndrome).
  6. The participant has a history, within the 6 months prior to screening, of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention.
  7. The participant has an irregular cardiac rhythm (e.g., atrial fibrillation, multifocal premature atrial contractions) which leads to difficulty with interpretation of ambulatory blood pressure monitoring (ABPM).
  8. The participant has a history of congestive heart failure, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
  9. The participant has type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin [HbA1c] >8.0%) at Screening.
  10. The participant has a history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
  11. The participant has an average clinic SBP >165 mm Hg or DBP >105 mm Hg at 1 or more visits during the Placebo Run-in Period.
  12. The participant's average clinic SBP or DBP measurement that increases or decreases by >10 mm Hg between Placebo Run-in visits (Day -14 to Day -7, or Day -7 to Day -1, or Day -14 to Day -1).
  13. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  14. The participant has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 times the upper limit of normal (ULN).
  15. The participant has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol.
  16. The participant has a history of alcoholism or illicit drug abuse within 5 years prior to the Screening Visit or is currently consuming >14 alcoholic drinks per week.
  17. The participant has a known hypersensitivity or allergies to febuxostat or any components of the formulations of this compound.
  18. The participant is taking or expected to take a medication as described in the excluded medication section.
  19. The participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. This criterion does not apply to those participants with successfully resected basal cell or stage I squamous cell carcinoma of the skin.
  20. The participant's estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73m3, where eGFR is calculated by the Central Laboratory using the Modification of Diet in Renal Disease (MDRD) formula at the Day -21 Screening Visit.
  21. The participant is noncompliant (<80% or >120%) with study medication during Placebo Run-In Period.
  22. The participant has an upper arm circumference less than 24 cm or greater than 42 cm.
  23. The participant's work shift includes any hour between 11 PM (2300) to 7 AM (0700).
  24. The participant has a baseline 24-hour ABPM reading of insufficient quality (as described in Appendix F of the protocol).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01496469

  Hide Study Locations
United States, Alabama
Foley, Alabama, United States
United States, California
Buena Park, California, United States
Carmichael, California, United States
Fresno, California, United States
Irvine, California, United States
Lomita, California, United States
Paramount, California, United States
Sacramento, California, United States
San Diego, California, United States
Wildomar, California, United States
United States, Connecticut
Milford, Connecticut, United States
United States, Florida
Fort Lauderdale, Florida, United States
Miami, Florida, United States
Tallahassee, Florida, United States
Tampa, Florida, United States
United States, Georgia
Dunwoody, Georgia, United States
Roswell, Georgia, United States
Suwanee, Georgia, United States
United States, Indiana
Avon, Indiana, United States
Indianapolis, Indiana, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maine
Biddeford, Maine, United States
United States, Missouri
Saint Peters, Missouri, United States
St. Louis, Missouri, United States
St. Peters, Missouri, United States
United States, Nevada
Henderson, Nevada, United States
Las Vegas, Nevada, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Glens Falls, New York, United States
United States, North Carolina
Greensboro, North Carolina, United States
Salisbury, North Carolina, United States
Shelby, North Carolina, United States
United States, North Dakota
Fargo, North Dakota, United States
United States, Ohio
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Lyndhurst, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Tipton, Pennsylvania, United States
United States, Texas
Carrollton, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Burke, Virginia, United States
Manassas, Virginia, United States
United States, Washington
Port Orchard, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Sponsors and Collaborators
Study Director: Medical Director, Clinical Science Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01496469     History of Changes
Other Study ID Numbers: TMX-67_206  U1111-1124-4638 
Study First Received: December 18, 2011
Results First Received: July 31, 2015
Last Updated: July 31, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Antirheumatic Agents
Gout Suppressants
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016